The landscape of biopharmaceuticals in China, particularly in the realm of human vaccines, is undergoing significant changes, as evidenced by the evolving journey of Chengda Biological Products CoThe company, primarily engaged in research, production, and commercialization of human vaccines, has faced challenges amidst a complex market environmentIts current flagship products include rabies vaccines and inactivated encephalitis vaccines, both derived from Vero cell technology, with a promising pipeline that includes a diploid rabies vaccine and a 15-valent HPV vaccine among others.

Despite its prominent position in the market, the financial performance of Chengda Biological has shown a downward trend in recent yearsFrom a revenue peak of 2.088 billion Yuan in 2021, it plummeted to 1.75 billion Yuan by 2023, indicating a continuous decline that reflects a 2.4% year-on-year drop in its earnings for the first three quarters of 2024. Equally concerning is the persistent decrease in net profit attributable to shareholders, which fell from 892 million Yuan in 2021 to approximately 466 million Yuan in 2023. The first three quarters of 2024 further highlighted this trajectory with profits decreasing by nearly 29% compared to the previous year.

The transformation of Chengda Biological's ownership structure also plays a critical role in its strategic directionNotably, the transition from a state-owned enterprise to a privately-held company raises both opportunities and challengesDeng Yong, the director of the Health Law Research and Innovation Center at Beijing University of Chinese Medicine, pointed out that the backing of Guangdong Min Investment as the primary driver for Shaoguan Gaoteng, allows for extensive support across multiple fronts including financing, management, and market resources, which could enhance Chengda Biological's growth prospects.

The narrative of Shaoguan Gaoteng's involvement began in earnest when it acquired a stake in Liaoning Chengda, Chengda Biological's parent company

Advertisements

This acquisition was marked by a series of strategic moves that began on January 1, 2020, with Shaoguan Gaoteng achieving a 5% stake through persistent purchasingThis stockholding rose to 12.46% just a month later after signing a share transfer agreement with Xinhua Union, establishing Shaoguan Gaoteng as the largest shareholder.

Throughout 2020, the tension escalated regarding the control of Chengda Biological, especially as the company sought to list on the Science and Technology Innovation BoardRegulatory concerns regarding ownership control emerged, prompting Shaoguan Gaoteng to publicly state in multiple notices that it was not pursuing actual control over Liaoning ChengdaThis assurance allowed the IPO to move forward, culminating in a successful listing in October 2021.

However, the real turning point came with the establishment of the new board of directors in February 2024, where Shaoguan Gaoteng nominated a majority of the directorsBy the end of February, a critical shareholders' meeting was set to position Shaoguan Gaoteng as the controlling entity of Liaoning Chengda, therefore enabling an indirect control over 54.67% of Chengda BiologicalThis transaction was particularly significant as it marked the exit of state capital from the ownership structure of a key player in China's vaccine market.

Further complicating matters, Chengda Biological also announced a tender offer priced at 25.51 Yuan per share, a move interpreted by analysts as a defensive tactic meant to signal to minority shareholders to reject the offer, consequently nullifying the obligation to fulfill the entire offerThis tender offer led to discussions around active management of public perceptions, as it seeks to prevent unfavorable consequences during a pivotal transition of ownership.

The landscape of the global vaccine market is promising, with projections indicating a substantial growth trajectory—expected to soar from a $46 billion market in 2021 to approximately $83 billion by 2025, reflecting a compound annual growth rate (CAGR) of about 16%. China’s vaccine market itself has been thriving, with estimates suggesting an increase from 101.77 billion Yuan in 2023 to an anticipated 124.5 billion Yuan in 2024. The ability of Chengda Biological to capture a greater share of this expanding market will be critical to its future profitability and resilience.

Chengda Biological has historically capitalized on its rabies vaccine, which has maintained a leading market share since 2008. The inactivated encephalitis vaccine stands as a unique offering in the domestic market, underscoring the company’s strategic positioning

Advertisements

Advertisements

Advertisements

Advertisements